


THOMSON PHARMA[®]

WORLD LEADING PHARMACEUTICAL COMPETITOR INTELLIGENCE SOLUTION



CONTAINS DATA DRAWN FROM

- 30,000 drug monographs
- 2,000,000 unique chemical structures
- 7,500 company profiles
- 1,000,000 basic inventions
- 3,000,000 patents
- 13,000 biologically-relevant drug targets
- 5,000,000 unique gene and protein sequences
- Over 6,000 medical journals
- 10,000 deals

WHEN YOU CAN BENEFIT

- Portfolio evaluation
- Drug discovery and development
- Planning and running clinical trials
- Registration and commercialization
- Market optimization
- Licensing and partnerships



NAVIGATE AN UNRIVALLED BREADTH AND DEPTH OF INFORMATION

Thomson Pharma[®] brings together the best of more than 40 data sources owned by Thomson Reuters in a single comprehensive solution.

This knowledge is extended and deepened by unique abstracts, commentaries and analysis prepared by our team of industry experts. You can link at a click between different types of content. No other data source puts so much information at your fingertips.

You can select the homepage that matches your user type, filter content by therapy area, and choose the way you receive vital information, relevant news and update alerts.

In place of your legacy indexing systems, multiple interfaces, and complex data sources, imagine how Thomson Pharma can simplify your information needs.

MORE WAYS TO LEARN

Thomson Pharma covers the entire competitor intelligence needs of pharmaceutical innovators — the latest drugs, compounds, genetic sequences and targets, clinical trials and licensing opportunities, patents, journals, conferences, academic articles and more.

Let's say you call up a drug report for a drug you're interested in. Instantly you can see its synonyms and trade names, its development status, and its approved uses and dosages. You can explore other drugs that act on the same target, or other drugs developed using the same technology.

Linking to its chemistry report, you'll see the activities reported for that compound, the drug & IP reports it's cited in, the synthetic methods used to produce it, the ADMET properties associated with it, its critical reaction data, and all the appropriate literature references.

With a click on the relevant company name, you'll see a company overview, its product portfolio, breaking news stories and financial performance.

Your data-mining efficiency will improve dramatically, gaining you time to do what you really want to do — ground-breaking research.

MORE WAYS TO INNOVATE

Thomson Pharma provides the essential data that can justify and speed your decision-making, meet your critical business challenges, and keep you abreast of the market.

Literature & News Report

SUMMARY

Title A Helicobacter hepaticus catalase mutant is hypersensitive to oxidative stress and suffers increased DNA damage

Source JOURNAL OF MEDICAL MICROBIOLOGY 2007, 56 (5):541-542

Authors Wang, Y, Wang, G, Haier, RZ

Address Haier, RZ, Univ Georgia, Dept Microbiol, Athens, GA 30602 USA

Cited references 18

Times cited 4

Total Links 4 (links combined): 24

Full text links 4 (links)

ABSTRACT

Catalase (KAT) is known to play an important role in oxidative stress resistance in many bacterial species and a homologous exists in Helicobacter hepaticus, a member of the enterohepatic helicobacter species. Here, a kKat mutant was constructed by gene deletion and its activities were investigated. Catalase activity was readily detected (the only mutant strain was deficient in, but not devoid of, activity). In activity and mid-type H. pylori generally contains higher levels of % O₂ for growth, while the kKat mutant could not growth of the H. hepaticus kKat strain was severely inhibited, positive side without exposure to SDS from H₂O₂ but the kKat offered no significant DNA damage by H₂O₂ treatment (1.10E-3) in the kKat mutant. Thus H. hepaticus kKat

The information in Thomson Pharma is divided into eight reports. Each report has a similar layout with tabs for moving between pages of information.

DEVELOPMENT STATUS

Therapy Area	Country	Status	Reference	Date
Autoimmune disease	US	Discontinued	132779	20 April 2004
Transplant rejection	US	Discontinued	132779	20 April 2004

Detailed Status for Jansynovics Inc.

Therapy Area	Country	Status	Reference	Date
Autoimmune disease	Canada	No Development Reported	-	10 November 2007
Insulin dependent diabetes	Canada	No Development Reported	-	10 Nov
Psoriasis	Canada	Phase 3 Clinical	124027	02 Dec
Psoriasis	Europe	Phase 3 Clinical	120461	05 Dec
Rheumatoid arthritis	Canada	No Development Reported	-	10 Nov
Transplant rejection	Canada	Phase 2 Clinical	414583	29 Jun
Transplant rejection	US	Phase 2 Clinical	414583	29 Jun

Detailed Status for Lex Biosciences Inc.

Therapy Area	Country	Status	Reference	Date
Urologic	Canada	Phase 3 Clinical	167261	26 February 2007
Urologic	Europe	Phase 3 Clinical	167261	26 February 2007
Urologic	India	Phase 3 Clinical	167261	26 February 2007

View the development status of a drug. Link out to the references where this information was gathered.

Deployed across your teams, the wealth of integrated content in *Thomson Pharma* promotes innovation and scientific breakthrough. All your company's users can gain an expert overview of the 'big picture' regarding your own organization and the pharmaceutical industry.

You can stay informed on the latest drugs, trials, news stories and patents. You'll get breaking company news, with links to the full stories and press releases. You'll be able to view meeting reports and conference proceedings, with key conference reports published overnight.

You'll be able to better manage your patent portfolio, finding opportunities to grow and generate revenue. You can discover which companies and inventors are working in promising areas, so you'll know who to hire, buy, work or merge with.

You'll find it easy to spin your thoughts into new areas, new lines of inquiry, new fields of study. You can identify gaps in the market and stay informed on the latest trends.

Most importantly of all, you'll ensure you don't miss the vital information that can affect your company's success.

MORE WAYS TO SEARCH

The intuitive web-based interface and consistent terminology of *Thomson Pharma* help you quickly identify the data you need.

Thomson Pharma contains multiple search options, from keyword to guided wizards prepared by experts, and index terms developed by leading information systems for quick, accurate hits. You can generate easy-to-read strategic reports that accumulate over time, and rank your results by company, therapy area, action, development status, and much more.

You can pull together data from multiple sources. You're never more than a click away from related information and intuitive analytical tools.

Despite this wealth of information, *Thomson Pharma* ensures you're never overwhelmed. Metadata fingerprints, Inxight StarTree® hyperbolic trees and flexible charting help put the data in context. Our editorial teams evaluate each item carefully and expertly to ensure you get only top quality, relevant search results.

MORE WAYS TO ORGANIZE

Each user can organize the information they use frequently in multiple personal report folders that can be set to send email alerts when new content arrives.

You can edit your saved results, and print, email, or export them to a Microsoft® Word or Excel, ISIS or BizInt file.

MORE WAYS TO PERSONALIZE

Thomson Pharma is a fully-customizable personal information center. Each user can create their own home page, receiving critical information the moment they log in.

Thomson Reuters can tailor *Thomson Pharma* to match your organization's way of working, and configure it to include your own third party data. Our services range from single corporate configurations to extensive, multi-layer bespoke solutions that deliver independent customization for different departments, sites or operational areas.

We'll work closely with you to identify, visualize and realize your development, ensuring that your users migrate to *Thomson Pharma* with the minimum of disruption, and continue to work in a manner they understand and find quick and easy.

The screenshot displays the Thomson Pharma interface. At the top, there's a 'Clinical Trials Watch' header with navigation icons for Feed, Alert, and Help. Below this is a 'Clinical Drugs News' section with a 'Latest' dropdown menu. The news items include headlines such as 'paliperidone effective, but not superior to risperidone, phase III schizophrenia trials' and 'Centocor begins phase II immune disorder trial of HuCAL-derived antibody'. A yellow callout box on the left says: 'Keep up to date with the latest information from meetings, clinical trials, drugs and much more, using home page alerts.' Below the news is a 'Master Fingerprint' visualization, which is a circular chart with segments representing different attributes like SWOT analysis, Market Share data, Literature Value, Structure, Licensing date, Sales, Launched, Approved, Clinical, Preclinical, and Strategic drug. A yellow callout box on the right says: 'Sophisticated search and visualization tools such as metadata fingerprints make it easy to drill down to the information you need, whatever your level of expertise.'

Scientific Head Offices

Americas

Philadelphia +1 800 336 4474
+1 215 386 0100

Europe, Middle East and Africa

London +44 20 7433 4000

Asia Pacific

Singapore +65 6411 6888
Tokyo +81 3 5218 6500

For a complete office list visit:

scientific.thomsonreuters.com/contact

GET A QUOTATION

Contact us today to request a no obligation quotation or visit scientific.thomsonreuters.com

